Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC).
Maria E. Cabanillas
Research Funding - Exelixis
Marcia S. Brose
Honoraria - Exelixis
Research Funding - Exelixis
David A. Ramies
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Yihua Lee
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Dale Miles
Employment or Leadership Position - Ex
Stock Ownership - Exelixis
Steven I. Sherman
Consultant or Advisory Role - Exelixis